この記事を読む

TKI+ベバシズマブでT790Mが減る?

Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with…

この記事を読む

中等度以上の自然気胸でもドレナージ不要

Conservative versus Interventional Treatment for Spontaneous Pneumothorax. Brown SGA et al. N Engl J Med. 2020 Jan 30;38…

この記事を読む

ALK-TKIはPD後もプラチナ+ペメトレキセドと併用した方がよい?

Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhib…

この記事を読む

多発か肺内転移かの鑑別アルゴリズム

A Novel Algorithm to Differentiate Between Multiple Primary Lung Cancers and Intrapulmonary Metastasis in Multiple Lung …

この記事を読む

オシメルチニブ耐性、治療するほど多様化

Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimert…

この記事を読む

LCNECの治療は小細胞癌レジメンがbetter

Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center r…

この記事を読む

ベバシズマブ+ペメトレキセドの維持療法

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous No…

この記事を読む

ROS1陽性に対するエヌトレクチニブ

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Drilon A …

この記事を読む

EGFRm+の脳病変フォローアップはどうするべきか

Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcin…

この記事を読む

メトホルミンはTKIの効果を上げる?

Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations…